Metabolism of the complex monofluorophosphate-alpha 2-macroglobulin in the rat.
Sodium monofluorophosphate (MFP) is a drug used in the treatment of primary osteoporosis. Following the intake of MFP, a small fraction of the drug is absorbed intact and forms a complex with alpha 2-macroglobulin (MFP-alpha 2M) inactivating the antiproteasic activity of the globulin. The complex has been shown to occur in the serum of rats and human being. This paper reports data on the metabolism of this complex in the rat. In vitro experiments showed that liver and bone tissue remove MFP-alpha 2M from the incubation medium. When the experiments were pursued beyond the time needed to reduce the complex concentration to very low levels, fluorine (F) reappears in the medium in two forms: bound to low molecular weight macromolecule/s (2,200 +/- 600 Da) and as ionic F. Concentrations of these F fractions increase while that of the complex decreases as a function of time. In vitro, uptake of the complex by liver or bone tissue was not affected by the presence of colchicine or methylamine. These drugs, however, inhibited intracellular metabolism of the complex, as indicated by the impairment of the return of F species to the extracellular space and the increase in F content of the tissue. The cellular receptors responsible for the uptake of the complex in liver and bone are insensitive to low concentration of calcium and inhibited by polyinosinic acid[5']. These features characterize the "scavenger" receptor, one of the two receptor types known to remove inactive alpha 2M from the circulation. Injection of polyinosinic acid [5'] to living rats also hindered the disappearance of the complex from serum. It is concluded that the metabolism of the MFP-alpha 2M complex involves binding to receptors, uptake by cells, lysosomal degradation and return of F bound to low molecular weight macromolecule/s to the extracellular space. It is assumed, however, that inorganic F is the final product of lysosomal hydrolysis of the protein moiety.
Laboratorio de Biología Osea, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Argentina.
L
L
Esteban
A
A
Rigalli
R C
RC
Puche
D000818:Animals; D001682:Biological Availability; D001842:Bone and Bones / Q000187:drug effects*; D005260:Female; D005459:Fluorides / Q000493:pharmacokinetics*; D005461:Fluorine / Q000032:analysis / Q000378:metabolism; D008099:Liver / Q000187:drug effects*; D046911:Macromolecular Substances; D008970:Molecular Weight; D010710:Phosphates / Q000493:pharmacokinetics*; D051381:Rats; D000511:alpha-Macroglobulins / Q000493:pharmacokinetics*
D046911:Macromolecular Substances; D010710:Phosphates; D000511:alpha-Macroglobulins; C012980:fluorophosphate; D005461:Fluorine; D005459:Fluorides